Catalyst has developed and optimized a proprietary method to create novel proteases that includes anti-C3 protease assets such as CB 2782 for the treatment of dry age-related macular degeneration (dAMD).

In April 2019, at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), Catalyst announced the presentation of new data on pegylated CB 2782.  The data demonstrated CB 2782-PEG’s potential for every three- or four-month intravitreal (IVT) dosing in humans which is a superior profile to clinical candidates in Phase 3 development with monthly or every two month IVT dosing.

The complement cascade is a series of molecular processes that play a central role in the body’s inflammatory and immune responses and helps to localize specific immune system cells at the site of infection or inflammation. In particular, C3 is a clinically validated target for the treatment of Geographic Atrophy (GA), a late-stage form of dAMD.

CB 2782-PEG is a long acting novel protease derived from human membrane type serine protease 1 (MTSP-1) that selectively cleaves C3 and has been shown to completely inhibit C3 in non-human primate studies with good tolerability after intraocular administration.

In 2017 Catalyst and Mosaic Biosciences entered into a strategic collaboration to develop novel protease-based anti-C3 intravitreal products. Catalyst maintains global commercial rights and these assets are available for partnering. Please contact our Business Development team for further information.